Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 7/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | FABP2 | P12104 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beclobrate SCHEMBL3950803 | 1.00 | OPRK1 (1.00) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL1935420 | 0.93 | OPRK1 (0.86) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL11071767 | 0.90 | OPRK1 (0.81) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL11063131 | 0.90 | OPRK1 (0.81) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL11070815 | 0.88 | OPRK1 (0.79) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL11470655 | 0.88 | OPRK1 (0.79) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL11068228 | 0.88 | OPRK1 (0.78) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL11072228 | 0.88 | OPRK1 (0.78) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL5997445 | 0.88 | OPRK1 (0.78) | OPRK1PPARACYP1A2CYP3A4ABCB11 | |
| SCHEMBL11074765 | 0.87 | OPRK1 (0.76) | OPRK1PPARACYP1A2CYP3A4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104523608-B | A kind of hydrophilic amide suitable for dewatering medicament is birdsed of the same feather flock together compound self assembly particulate medicine-releasing system and preparation method thereof | 张建祥 | 2018-04-24 | — | — | CN | claimed |
| EP-2649989-B1 | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof | UNIV KING SAUD (SA) | 2017-10-18 | — | — | EP | claimed |
| EP-2251038-B1 | SOLID DISPERSION, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND PROCESSES FOR THE PRODUCTION OF BOTH | ASKA PHARM CO LTD (JP) | 2017-05-10 | — | — | EP | claimed |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-12-22 | — | — | US | claimed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | claimed |
| EP-2941252-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | Catabasis Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | claimed |
| CN-104840963-A | Medicine composition containing lipoprotein-associated phospholipase A2 inhibitors and application thereof | HEBEI DONGKANG BIOTECHNOLOGY CO LTD | 2015-08-19 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-104523608-A | Hydrophilic amide polymer self-assembly particle drug release system suitable for hydrophobic drugs and preparation method thereof | ZHANG JIANXIANG | 2015-04-22 | — | — | CN | claimed |
| WO-2014107730-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | WO | claimed |
| US-20020003179-A1 | Media milling | SKYEPHARMA AG (CH) | 2002-01-10 | — | — | US | claimed |
| WO-2001085345-A1 | MEDIA MILLING | RTP PHARMA INC. (US) | 2001-11-15 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6211206-B1 | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| US-6211207-B1 | ANTIDIABETIC AGENTS AND INSULIN SENSITIVITY ENHANCER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6133293-A | INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998031360-A1 | PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT | PHARMA PASS (FR) | 1998-07-23 | — | — | WO | claimed |
| US-4483999-A | Phenoxy alkanoic acid derivatives having the ability to lower the level of fatty substances in the blood | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1984-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | OPRK1 3802/4885PPARA 112/4885CYP1A2 720/4885 |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | LIPC, PNLIP, LIPA | OPRK1 4501/4885PPARA 275/4885CYP1A2 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.